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Hypertension has a continuous, age-related risk of mortal-ity from ischemic heart disease.1 At least 30% of adults 
have a history of hypertension in developed countries,2,3 and 
hypertension is independently associated with adverse cardiac 
outcome after acute myocardial infarction (MI).4–11 However, 
the mechanisms for this association are unclear. Patients who 
present with acute ST-segment–elevation myocardial infarction 
(STEMI) and a history of hypertension are older and generally 
have a higher burden of risk factors,11,12 except for cigarette 
smoking which associates with male sex and younger age.11,12 
The size of infarction is a key determinant of survival post-
MI, but previous studies11,12 have not found any association 
between hypertension status and infarct size. Therefore, the 
mechanisms underlying the association between hypertension 
status and health outcomes post-MI remain unclear.
Hypertension is a risk factor for coronary heart disease.13 
The pathophysiology includes left ventricular hypertrophy,14 
coronary endothelial dysfunction,15 accelerated coronary athero-
sclerosis,16,17 abnormal coronary artery remodeling,18 coronary 
microvascular dysfunction,19 and epicardial fat.20 Accordingly, 
preexisting coronary heart disease may predispose patients 
with antecedent hypertension to enhanced myocardial reperfu-
sion injury. Severe microvascular injury within the infarct zone 
manifests acutely as microvascular obstruction affecting about 
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half of all-comers with STEMI,21,22 and subsequently resolving 
in half of these patients by 10 days.22 In patients with persis-
tent microvascular obstruction, progressive irreversible capillary 
degradation occurs leading to infarct zone hemorrhage, which is 
an independent predictor of death or heart failure in the longer 
term.21,22 To date, the associations between antecedent hyperten-
sion and microvascular injury post-MI are unclear.
We investigated the natural history of hypertension status, 
microvascular pathology, and prognosis in all-comers with acute 
STEMI. We measured microvascular function directly in the cul-
prit coronary artery acutely using a sensor mounted on an intra-
coronary guidewire and noninvasively using the surface ECG. We 
subsequently used multiparametric cardiac magnetic resonance 
(CMR) to assess the evolution of infarct pathologies and left ven-
tricular function and volumes at 2-day and 6-month post-MI.
We hypothesized that a history of hypertension would be 
associated with enhanced microvascular dysfunction within 
the culprit coronary artery acutely, and more abundant micro-
vascular pathologies, including microvascular obstruction and 
myocardial hemorrhage, independent of the size of infarc-
tion, when assessed using CMR 2 days later. This hypothesis 
implicates microvascular damage within the infarct zone as an 
underpinning mechanism leading to less myocardial salvage, 
greater adverse left ventricular remodeling, and an increased 
risk of heart failure and death after an acute MI.
Methods
The data that support the findings of this study can be requested from 
the following URL: http://www.CORportal.net.
Study Population
We performed a prospective cohort study in a regional cardiac center 
between July 14, 2011, and November 22, 2012. Written informed 
consent was obtained from all of the participants.
A history of hypertension was prospectively recorded if patients 
were prescribed antihypertensive treatment or had successive blood 
pressure (BP) measurements that were ≥140/90 mm Hg on at least 
2 different days during the index hospitalization.23 Noninvasive BP 
was measured in recumbent patients using an oscillometric method 
using an arm cuff pressure-sensitive transducer (GE CRITIKON, GE 
Healthcare, Amersham, United Kingdom) and automated medical 
patient monitoring system (DINAMAP and CARESCAPE Monitor 
B850, GE Medical Systems Information Technologies). Patients were 
categorized as having hypertension or not.
Patients were eligible if they had an indication for primary per-
cutaneous coronary intervention (PCI) or thrombolysis for acute 
STEMI.24 Exclusion criteria included contraindications to CMR, 
for example, a pacemaker. The study was approved by the National 
Research Ethics Service (reference 10-S0703-28). Acute STEMI 
management followed contemporary guidelines24 (Methods in the on-
line-only Data Supplement). The ClinicalTrials.gov identifier is URL: 
http://www.clinicaltrials.gov. Unique identifier: NCT02072850.
Electrocardiogram
A 12-lead ECG was obtained before coronary reperfusion and 60 
minutes afterward. The extent of ST-segment resolution on the ECG 
assessed 60 minutes after reperfusion compared with the baseline 
ECG before reperfusion24 was expressed as complete (≥70%), incom-
plete (30% to <70%), or none (≤30%).
Coronary Angiogram Acquisition and Analyses
Coronary angiograms were acquired during usual care with cardiac cathe-
ter laboratory X-ray (Innova, GE Healthcare) and information technology 
equipment (Centricity, GE Healthcare). The angiograms were analyzed 
by trained observers (J. Carberry, V.T. Yue May) who were blinded to all 
other clinical and CMR data. The Thrombolysis In Myocardial Infarction 
(TIMI) coronary flow grade25 and frame count26 were assessed at initial 
angiography and at the end of the procedure. TIMI myocardial perfu-
sion grade27 was assessed at the end of the procedure (Methods in the 
online-only Data Supplement). The TIMI frame count and perfusion 
grade are angiographic measures of microvascular function.
Direct, Invasive Measurement of Microvascular 
Function in the Culprit Coronary Artery
A coronary pressure- and temperature-sensitive guidewire (St Jude 
Medical, St Paul, MN) was used to measure index of microvascular 
resistance (IMR) and coronary flow reserve (CFR) in the culprit coro-
nary artery at the end of PCI.28–32 The guidewire was calibrated out-
side the body, equalized with aortic pressure at the ostium of the guide 
catheter and then advanced to the distal third of the culprit artery. This 
thermodilution method is based on the following basic relationship: 
flow=volume / mean transit time. CFR is defined as the ratio of peak 
hyperemic to resting flow (CFR=flow at hyperemia / flow at rest). Flow 
is the ratio of the volume (V) divided by the mean transit time (Tmn). 
Thus, CFR can be expressed as follows: CFR=(V/Tmn) at hyper-
emia/ (V/Tmn) at rest. Assuming the epicardial volume (V) remains 
unchanged, CFR can be calculated as follows: CFR=Tmn at rest / Tmn 
at hyperemia. CFR and IMR are distinct physiological parameters. 
CFR reflects epicardial and microcirculatory function, by contrast, 
IMR is a direct invasive measure of microvascular resistance. IMR is 
defined as the distal coronary pressure multiplied by the mean transit 
time of a 3 mL bolus of saline at room temperature during maximal 
coronary hyperemia, measured simultaneously (mm Hg×s or units).28–32
Hyperemia was induced by 140 μg/kg per minute of intravenous 
adenosine preceded by a 2 mL intracoronary bolus of 200 µg of ni-
trate. The mean aortic and distal coronary pressures were recorded 
during maximal hyperemia. We have previously found IMR to be 
highly repeatable when assessed by duplicate measurements 5 min-
utes apart in 12 consecutive STEMI patients at the end of PCI.30
Laboratory Analyses
Serial systemic blood samples were obtained immediately after 
reperfusion in the cardiac catheterization laboratory and subsequently 
on the first day (06:00–07:00 hours) during the initial inpatient stay in 
the Coronary Care Unit.
CRP (C-reactive protein) was measured in the hospital biochem-
istry laboratory using a particle-enhanced immunoturbidimetric assay 
method (Cobas C501, Roche), and the manufacturer’s calibrators and 
quality control material, as a biochemical measure of inflammation. 
The high-sensitive assay CRP measuring range is 0.1 to 250 mg/L. 
The expected CRP values in a healthy adult are <5 mg/L, and the 
reference range in our hospital is 0 to 10 mg/L. IL (interleukin)-6 was 
measured using a high-sensitivity enzyme-linked immunosorbent as-
say (ELISA; R&D Systems, Oxon, United Kingdom).33 The limit of 
detection is <0.1 pg/mL, and the intra-assay coefficient of variation 
was 9.1%. NT-proBNP (N-terminal Pro-B-type natriuretic peptide) 
was measured in a research laboratory using an electrochemilumi-
nescence method (e411, Roche) and the manufacturers’ calibrators 
and quality control material. The limit of detection for IL-6 and NT-
proBNP are 6.5 pg/mL and 5 pg/mL, respectively. Long-term coef-
ficient of variations of low and high controls are typically <5% and 
were all within the manufacturers’ range.
CMR Imaging
We used CMR to provide reference data on left ventricular func-
tion, pathology, and surrogate outcomes (Figure 1). CMR was per-
formed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 
1.5-Tesla scanner with a 12-element phased array cardiac surface 
coil.32 The imaging protocol34,35 (Methods in the online-only Data 
Supplement) included cine CMR with steady-state free precession, 
T2-mapping,22,36,37 T2*-mapping,22 and delayed-enhancement phase-
sensitive inversion-recovery pulse sequences.38 The scan acquisitions 
were spatially coregistered and also included different slice orienta-
tions to enhance diagnostic confidence.
Imaging Analyses
The CMR analyses are described in detail in the online-only Data 
Supplement. Left ventricular dimensions were indexed to body sur-
face area.
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Infarct Definition and Size
The presence of acute infarction was established based on abnor-
malities in cine wall motion, rest first-pass myocardial perfu-
sion, and delayed-enhancement imaging in 2 imaging planes. The 
myocardial mass of late gadolinium (grams) was quantified using 
computer-assisted planimetry and the territory of infarction was 
delineated using a signal intensity threshold of >5 SDs above a 
remote reference region and expressed as a percentage of total left 
ventricular mass.39
Microvascular Obstruction
Microvascular obstruction was defined as a dark zone on early gad-
olinium enhancement imaging 1, 3, 5, and 7-minute postcontrast 
injection that remained present within an area of late gadolinium 
enhancement at 15 minutes.
Myocardial Edema
The extent of myocardial edema was defined as left ventricu-
lar myocardium with pixel values (T2) >2 SDs from remote 
myocardium.40–42
Myocardial Salvage
Myocardial salvage was calculated by subtraction of percent infarct 
size from percent area-at-risk, as reflected by the extent of edema.40–42 
The myocardial salvage index was calculated by dividing the myocar-
dial salvage area by the initial area-at-risk.
Left Ventricular Remodeling
An increase in left ventricular volume at 6 months from baseline was 
taken to reflect left ventricular remodeling.35
Myocardial Hemorrhage
On the T2* CMR maps, a region of reduced signal intensity within 
the infarcted area, with a T2* value of <20 ms22,43 was considered to 
confirm the presence of myocardial hemorrhage.
Prespecified Health Outcomes
We prespecified adverse health outcomes that are pathophysiologi-
cally linked with STEMI.44,45 The primary composite outcome was 
(1) all-cause death or first heart failure event after the initial hospital-
ization (Methods in the online-only Data Supplement).
Statistical Analyses
The sample size calculation and statistical methods are described in 
the online-only Data Supplement. All P values are 2-sided and a P 
value >0.05 indicates the absence of a statistically significant effect. 
Statistical analyses were performed using R version 2.15.1 or SAS v 
9.3 or higher versions of these programs.
Results
Patient Characteristics
Of 372 patients with acute STEMI who were screened, 324 
(mean age, 59 [12)] years; 237 [73%] male, 105 [32%] with 
hypertension) were enrolled (Table 1; Figure 2). The reasons 
for not being enrolled in the study are detailed in Figure 2. 
None of the participants had a new diagnosis of hypertension 
during the index admission.
Figure 1. Two patients, one with a history of hypertension (A) and the other without (B) presented similarly with acute anterior ST-segment–elevation 
myocardial infarction and were treated by primary percutaneous coronary intervention (PCI) with stents. The antithrombotic therapies, including aspirin, 
clopidogrel, and unfractionated heparin, were similar. Each patient had normal antegrade flow in the culprit coronary artery (Thrombolysis In Myocardial 
Infarction grade 3) at the end of PCI. Multiparametric cardiovascular magnetic resonance (CMR) imaging was performed 2 d and 6 mo later. Top, A, Imaging 
obtained from a 52-year-old man with a history of current hypertension. The symptom-to-balloon time was 1.4 h. The coronary angiogram revealed a proximal 
occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 200/125 mm Hg and measured 181/117 mm Hg postcoronary 
angioplasty. Two days later, CMR disclosed myocardial hemorrhage specifically revealed by T2* mapping (yellow arrows) and transmural infarction of the 
anteroseptal wall of the left ventricle (LV; yellow arrows) associated with microvascular obstruction revealed by contrast CMR. Invasive assessment of 
microvascular function using a diagnostic guidewire placed in the culprit coronary artery at the end of primary PCI indicated severe microvascular injury. The 
index of microvascular resistance measured 92 which is substantially increased (reference range <25). The initial infarct size was 38.9%, and the LV ejection 
fraction (LVEF) and LV end-diastolic volume indexed to body surface area (LVEDVi) were 48.5% and 90.2 mL/m2, respectively. Six months later, infarct size 
was 26.7% of LV mass, and the LVEDVi was 127 mL/m2. This is in-keeping with >20% in LVEDVi, that is, adverse remodeling. This patient went to have 
an unplanned admission for heart failure treatment on day 493 of follow-up. Bottom, B, Imaging obtained from a 58-year-old man with no prior history of 
hypertension. The symptom-to-balloon time was 2.2 h. The angiogram also revealed a proximal occlusion of the left anterior descending artery. Blood pressure 
before coronary angioplasty was 109/71 mm Hg and measured 99/60 mm Hg postcoronary angioplasty. Microvascular resistance in the culprit coronary artery 
was normal. Two days later, there was a small amount of microvascular obstruction as revealed by contrast-enhanced CMR (yellow arrows), and no evidence of 
myocardial hemorrhage (T2 star parametric map). The initial infarct size was 32.4%, and the LVEF and LVEDVi were 36.9% and 126.4 mL/m2, respectively. Six 
months later, infarct size was 15.2% of left ventricular mass, and the LVEDVi was 98.2 mL/m2. This patient had an uncomplicated clinical course.
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Table 1. Clinical and Angiographic Characteristics of 324 STEMI Patients Categorized According to a History of Hypertension
Characteristics*
All Patients
No History of Hypertension History of Hypertension
P Value
Normal BP High BP Normal BP High BP
n=324 n=154 n=63 n=67 n=38
Age, y 59 (12) 58 (11) 55 (10) 66 (11) 60 (12) <0.001 (A)
Male sex, n (%) 237 (73) 110 (71) 52 (83) 45 (67) 28 (74) 0.226
BMI, kg/m2 29 (5) 28 (5) 29 (5) 29 (5) 30 (4) 0.069 (A)
Medical history
  Current smoking, n (%) 196 (61) 101 (66) 42 (67) 30 (45) 22 (58) 0.023
  Hypercholesterolemia, n (%) 94 (29) 33 (21) 9 (14) 33 (49) 18 (47) <0.001
  Diabetes mellitus†, n (%) 34 (11) 15 (10) 3 (5) 12 (18) 4 (11) 0.113
  Previous angina, n (%) 40 (12) 17 (11) 5 (8) 10 (15) 8 (21) 0.224
  Previous myocardial infarction, n (%) 25 (8) 8 (5) 5 (8) 7 (10) 4 (11) 0.374
  Previous PCI, n (%) 18 (6) 7 (5) 5 (8) 5 (8) 1 (3) 0.583
Presenting characteristics
  Heart rate, bpm 78 (17) 75 (16) 82 (19) 77 (15) 82 (17) 0.012 (A)
  Systolic blood pressure, mm Hg 135 (25) 124 (17) 159 (16) 124 (20) 163 (18) <0.001 (A)
  Diastolic blood pressure, mm Hg 79 (14) 73 (10) 93 (9) 71 (11) 95 (9) <0.001 (A)
  Symptom onset to reperfusion time, min 174 (120–315) 171 (112–313) 208 (132–318) 209 (129–445) 144 (110–220) 0.028 (KW)
  Ventricular fibrillation‡, n (%) 21 (7) 10 (7) 1 (2) 9 (13) 1 (3) 0.045
  Killip class at presentation, n (%) 0.127
   I 233 (72) 116 (75) 42 (67) 43 (64) 31 (82)  
   II 68 (21) 31 (20) 16 (25) 14 (21) 6 (16)  
   III/IV 23 (7) 7 (5) 5 (8) 10 (15) 1 (3)  
ST-segment resolution, n (%) 0.166
  Complete ≥70% 148 (46) 81 (53) 25 (40) 30 (46) 11 (29)
  Incomplete 30% to <70% 127 (39) 54 (35) 28 (44) 26 (39) 18 (47)  
  None ≤30% 48 (15) 19 (12) 10 (16) 10 (15) 9 (24)  
Reperfusion strategy, n (%) 0.804
  Primary PCI 302 (93) 144 (94) 60 (95) 61 (91) 35 (92)
  Rescue PCI (failed thrombolysis) 14 (4) 5 (3) 2 (3) 5 (8) 2 (5)  
  Successful thrombolysis 8 (3) 5 (3) 1 (2) 1 (2) 1 (3)  
Coronary angiography
  No. of diseased arteries§, n (%) 0.037
   1 174 (54) 94 (61) 28 (44) 37 (55) 13 (34)  
   2 99 (31) 43 (28) 23 (37) 17 (25) 16 (42)  
   3 45 (14) 14 (9) 12 (19) 11 (16) 8 (21)  
  Culprit coronary artery, n (%) 0.208
   LM 6 (2) 3 (2) 0 2 (3) 1 (3)  
   LAD 121 (37) 61 (40) 27 (43) 24 (36) 9 (24)
   LCX 59 (18) 25 (16) 14 (22) 8 (12) 10 (26)  
   RCA 144 (44) 68 (44) 22 (35) 35 (52) 19 (50)  
TIMI coronary flow grade pre-PCI, n (%) 0.398
   0/1 236 (73) 108 (70) 49 (78) 47 (70) 31 (82)  
   2/3 88 (27) 46 (30) 14 (22) 20 (30) 7 (18)  
(Continued )
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TIMI coronary flow grade post-PCI, n (%) 0.052
   0/1 4 (1) 0 2 (3) 2 (3) 0  
   2/3 320 (99) 154 (100) 61 (97) 65 (97) 38 (100)  
Microvascular function (angiography)
  TIMI frame count pre-PCI 30 (18–47) 28 (18–43) 24 (16–28) 38 (28–58) 34 (19–42) 0.068 (KW)
  TIMI frame count post-PCI 16 (10–25) 14 (10–23) 17 (12–30) 18 (10–24) 19 (10–26) 0.266 (KW)
  TIMI blush grade post-PCI, n (%) 0.505
   0 70 (23) 33 (23) 15 (25) 13 (20) 9 (24)  
   1 17 (6) 5 (3) 4 (7) 7 (11) 1 (3)  
   2 157 (51) 71 (49) 28 (48) 35 (54) 21 (57)  
   3 65 (21) 37 (25) 12 (20) 10 (15) 6 (16)  
Microvascular function (intracoronary sensor)
  Index of microvascular resistance 24 (15–44) 26 (15–43) 23 (15–37) 24 (15–50) 25 (17–49) 0.929 (KW)
  Coronary flow reserve 1.6 (1.1–2.1) 1.5 (1.1–2.0) 1.8 (1.2–2.3) 1.6 (1.1–2.1) 1.4 (1.1–1.8) 0.170 (KW)
  Resistance reserve ratio 1.8 (1.4–2.5) 1.8 (1.3–2.5) 2.3 (1.7–3.0) 1.8 (1.3–2.3) 1.8 (1.5–2.3) 0.261 (KW)
Treatment in the catheter laboratory, n (%)
  Aspiration thrombectomy 236 (73) 107 (70) 52 (83) 49 (73) 27 (71) 0.254
  Glycoprotein IIb/IIIa inhibitor 297 (92) 144 (94) 56 (89) 59 (88) 36 (95) 0.402
Medical therapy
  ACE-I or ARB 320 (99) 151 (98) 62 (98) 67 (100) 38 (100) 0.796
  β-Blocker 308 (95) 142 (92) 61 (97) 67 (100) 36 (95) 0.058
  Statin 324 (100) 154 (100) 63(100) 67 (100) 38 (100) 1.000
Antiplatelet therapy at discharge
   Aspirin 323 (100) 153 (99) 63 (100) 67 (100) 38 (100) 1.000
   Clopidogrel 321 (99) 152 (99) 62 (98) 67 (100) 38 (100) 0.796
Blood results on admission
  Creatinine, µg/L 76 (65–89) 74 (65–87) 75 (64–87) 77 (70–91) 79 (65–98) 0.276 (KW)
  C-reactive protein, mg/L 4 (2–7) 3 (2–6) 4 (2–8) 3 (2–9) 4 (2–7) 0.233 (KW)
  Interleukin-6, pg/mL 7 (4–11) 7 (4–10) 6 (5–11) 8 (4–21) 9 (6–15) 0.503 (KW)
  NT-proBNP 864  
(345–1637)
651  
(322–1437)
1208  
(352–1637)
1208  
(576–1924)
702  
(299–1175)
0.310 (KW)
  Troponin T, ng/L 1710  
(110–5099)
1628  
(256–4375)
1504  
(106–5580)
1931  
(101–5244)
1981  
(210–5108)
0.976 (KW)
Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, 
and elevated jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. ACE-I indicates angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; LAD, left anterior descending coronary artery; LCX, left circumflex 
coronary artery; LM, left main coronary artery; NT-proBNP, N-terminal Pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention; RCA, right 
coronary artery; STEMI, ST-segment–elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
*Data are reported as mean (SD), median (interquartile range), or N (%) as appropriate. P values have been obtained from 1-way ANOVA (A), Kruskal-Wallis 
test (KW), or Fisher test. TIMI flow grades pre- and post-PCI were grouped 0/1 vs 2/3 for this analysis. 
†Diabetes mellitus was defined as a history of diet-controlled or treated diabetes mellitus.
‡Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure. 
§Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual 
assessment and whether or not there was left main stem involvement. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) in 
the table represent measurements obtained at the start of emergency PCI. High blood pressure is defined as having SBP >140 mm Hg and DBP >80 mm Hg 
during the index admission.
Table 1. Continued
Characteristics*
All Patients
No History of Hypertension History of Hypertension
P Value
Normal BP High BP Normal BP High BP
n=324 n=154 n=63 n=67 n=38
D
ow
nloaded from
 http://ahajournals.org by on May 1, 2019
Carrick et al  Hypertension, Acute MI, and Prognosis  725
Compared with patients without a history of hyperten-
sion, patients with a history of hypertension were older, had 
a history of hypercholesterolemia more often, but a history 
of cigarette smoking less often, and were more likely to have 
ventricular fibrillation at presentation and multivessel coro-
nary artery disease (Table 1).
Microvascular Injury in the Culprit Coronary 
Artery and Inflammation
Angiographic parameters of blood flow and perfusion in the 
culprit coronary artery, IMR, and ST-segment resolution on 
the ECG (none versus partial versus complete) were similar 
between the groups (Table 1).
On day 1, circulating CRP, IL-6, and neutrophils and mono-
cyte levels were also similar between the groups (Table 1).
CMR Imaging Findings
Three hundred twenty-four patients underwent CMR imaging 2.0 
(1.8) days later, and 300 (93%) patients had follow-up CMR at 6 
months (Table 2; Figure 2). Case examples are shown in Figure 1.
Infarct size was similar in patients with or without a his-
tory of hypertension (Table 2). However, left ventricular mass 
index at baseline was associated with a history of hyperten-
sion in men (Table 2) and in both men and women with hyper-
tension at 6-month post-STEMI (Table 2).
Left ventricular ejection fraction improved in all patients, 
however, compared with patients without a history of hyper-
tension, the increase in ejection fraction was less in patients 
with a history of hypertension (Table 2).
Sex Differences and History of Hypertension
Left ventricular mass reduced to a lesser extent by 6 months in 
women with hypertension compared with in women without 
hypertension (Table 2).
BP at Initial Presentation
We observed associations between BP at the start of emer-
gency PCI (normal BP [systolic BP ≤140 mm Hg; diastolic 
BP ≤80 mm Hg]; high BP [systolic BP >140 mm Hg; diastolic 
BP >80 mm Hg] and clinical characteristics notably body 
mass index [normal BP versus high BP: 28.4 (4.8) versus 29.6 
(4.7) kg/m2; P=0.042] but not vascular risk factors [smoking 
P=0.54]; hypercholesterolemia [P=0.59]) and microvascu-
lar dysfunction at the end of PCI as revealed by ST-segment 
Figure 2. Study flow diagram of the cohort study. 
CMR indicates cardiovascular magnetic resonance; 
and STEMI, ST-segment–elevation myocardial 
infarction.
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Table 2. Cardiac MRI Findings at 2 Days and 6 Months Postreperfusion in 324 STEMI Patients Categorized According to History of Hypertension
Characteristics*
All Patients
No History of Hypertension History of Hypertension
P Value
Normal BP High BP Normal BP High BP
n=321 n=153 n=63 n=65 n=38
CMR findings 2-d post-MI
  LV ejection fraction, % 55 (10) 55 (10) 53 (9) 56 (10) 56 (9) 0.178 (A)
  LV end-diastolic volume index, mL/m2
   Men 82 (15) 82 (14) 83 (15) 82 (17) 83 (15) 0.958 (A)
   Women 72 (12) 73 (12) 73 (16) 73 (10) 70 (13) 0.901 (A)
  LV end-systolic volume index, mL/m2
   Men 38 (13) 39 (14) 40 (13) 37 (14) 38 (11) 0.804 (A)
   Women 32 (10) 32 (10) 35 (10) 32 (9) 29 (9) 0.516 (A)
  LV mass index, g/m2
   Men 73 (15) 70 (14) 76 (13) 76 (17) 77 (16) 0.019 (A)
   Women 58 (10) 55 (8) 64 (15) 58 (9) 61 (14) 0.065 (A)
Infarct characteristics
  Infarct size, %LV mass 16 (7 to 27) 15 (5 to 25) 19 (8 to 33) 20 (7 to 29) 15 (7 to 22) 0.102 (KW)
  Myocardial salvage index, % 
of LV mass
63 (24) 66 (26) 58 (25) 61 (22) 63 (19) 0.174 (A)
  Late microvascular 
obstruction, n (%)
164 (51) 75 (49) 33 (52) 36 (54) 19 (50) 0.902 (A)
  Late microvascular 
obstruction, %LV mass
0 (0 to 4) 0 (0 to 3) 1 (0 to 4) 1 (0 to 6) 0 (0 to 3) 0.342 (KW)
  Myocardial hemorrhage, n (%) 101 (41) 44 (38) 20 (39) 25 (49) 12 (46) 0.514 (A)
CMR findings 6-mo post-MI (n=267)
  LV ejection fraction at 6 mo, % 63 (57 to 69) 64 (59 to 70) 60 (55 to 66) 62 (54 to 69) 65 (59 to 71) 0.049 (KW)
  Change in LV ejection fraction 
at 6 mo, %
7 (8) 8 (8) 7 (7) 4 (7) 7 (10) 0.037 (A)
  LV mass index, g/m2
   Men 63 (56 to 71) 61 (54 to 69) 63 (57 to 71) 67 (59 to 77) 68 (62 to 74) 0.004 (KW)
   Women 53 (9) 49 (6) 54 (6) 57 (10) 60 (9) <0.001 (A)
  Change in LV mass index at 6 mo, g/m2
   Men −8 (13) −7 (14) −10 (13) −7 (12) −7 (9) 0.641 (A)
   Women −5 (8) −7 (7) −6 (8) 0 (11) −4 (5) 0.022 (A)
  LV end-systolic volume index at 6 mo, mL/m2
   Men 32 (23 to 41) 30 (22 to 37) 35 (28 to 41) 33 (22 to 43) 31 (22 to 36) 0.208 (KW)
   Women 27 (10) 25 (10) 29 (10) 30 (10) 26 (10) 0.231 (A)
  Change in LV end-systolic volume index at 6 mo, mL/m2
   Men −4 (13) −5 (13) −4 (10) 0 (15) −6 (13) 0.179 (A)
   Women −5 (8) −6 (7) −7 (8) −2 (9) −4 (9) 0.182 (A)
BMI indicates body mass index; BP, blood pressure; CMR, cardiac magnetic resonance; LV, left ventricle; MI, myocardial infarction; MRI, magnetic 
resonance imaging; and STEMI, ST-segment–elevation myocardial infarction.
Area-at-risk was measured with T2-mapping. Data are given as n (%) or mean (SD). P values were obtained from a 1-way ANOVA (A), Kruskal-Wallis 
test (KW), or a Fisher test. Native T1 (ms) was not associated with hypertension status (antecedent hypertension, yes vs no: remote zone, P=0.266; infarct 
zone, P=0.508; infarct core, P=0.205). High blood pressure is defined as having systolic BP (SBP)> 140 mm Hg and diastolic BP (DBP) >80 mm Hg during 
the index admission.
*Data are reported as mean (SD), median (interquartile range), or n (%) as appropriate. LV ejection fraction was missing in 24 subjects at follow-up. LV 
end-diastolic volume index at follow-up was missing in 16 men and 8 women.
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resolution (complete, none, partial: [normal BP versus high 
BP] 111 [50.5%], 29 [13.2%], 80 [36.4%] versus 36 [35.6%], 
19 [18.8%], 46 [45.5%]; P=0.041).
Multivariable Associations Between Hypertension 
and Coronary Microvascular Pathology
Myocardial Hemorrhage
In a binary logistic regression model with baseline character-
istics, a history of hypertension was a multivariable associate 
of myocardial hemorrhage (odds ratio, 1.81; [95% confidence 
interval, 0.98–53.34]; P=0.059; Table 3), albeit with wide 
confidence intervals.
Microvascular Dysfunction and Health Outcomes in 
the Longer Term
All (n=324) of the patients had long-term follow-up data 
completed. The median duration of follow-up was 1500 days 
(postdischarge censor duration [range] 1236 to 1801 days). 
Forty-seven (15%) patients died or experienced a first heart 
failure event during the index hospitalization or postdischarge. 
These events included 4 cardiovascular deaths, 11 noncardio-
vascular deaths, 2 deaths of undetermined cause, and 30 epi-
sodes of heart failure (Killip class 3 or 4 heart failure [n=28] or 
defibrillator implantation n=2). Twenty-three (7%) patients died 
or experienced a first heart failure hospitalization postdischarge.
A history of hypertension (odds ratio, 2.53; [95% con-
fidence interval, 1.28–4.98]; P=0.007) was a multivariable 
associate of all-cause death or heart failure (Table 4).
Discussion
We have undertaken a large prospective imaging cohort study of 
hypertension status, microvascular pathophysiology, and long-
term prognosis in patients with an acute STEMI. Uniquely, our 
study enrolled a high proportion of screened patients (nearly 9 of 
every 10 assessed), followed by serial multimodality assessments 
including use of invasive and noninvasive tests of reperfusion 
injury, circulating measures of inflammation, serial imaging of 
infarct pathology and remodeling, and follow-up for health out-
comes over a median of 4 years in all of the study participants.
The main findings are that antecedent hypertension was 
associated with (1) older age and less cigarette smoking; (2) 
a 2-fold increased likelihood of myocardial hemorrhage, albeit 
with wide confidence intervals, and less improvement in left 
ventricular systolic function at 6 months; (3) sex differences, 
specifically, for the associations between hypertension status 
and left ventricular outcomes in women but not in men; and (4) 
>2-fold increased risk of all-cause death or heart failure during 
a median of 4 years follow-up. Antecedent hypertension was 
not associated with infarct size, reperfusion injury, or systemic 
inflammation. BP status at initial presentation was associated 
with age, body mass index, and reperfusion injury as revealed 
by ST-segment resolution at the end of the PCI procedure.
Hypertension and Prognosis After Acute STEMI
In line with prior studies,11,12 we found that a history of hyper-
tension is associated with risk factors for cardiovascular 
disease including age, smoking (less common),46 and hyper-
cholesterolemia (more common).
We also found that a history of hypertension was inde-
pendently associated with an increased risk of all-cause death 
or hospitalization for heart failure. This result extends the 
evidence from previous studies. Notably, Reinstadler et al11 
found that antecedent hypertension was associated with a >3-
fold risk of major adverse cardiac events at 12 months in a 
clinical trial population of 792 patients with acute STEMI.
Antecedent Hypertension, Sex, and Remodeling
Recent studies have reported conflicting information on the 
associations between antecedent hypertension and sex.11,12 
Changes in left ventricular ejection fraction and remodeling 
at 6 months, including left ventricular end-systolic volume 
and mass, were less favorable in women with hypertension 
compared with women without hypertension. The enhanced 
Table 3. Multivariable Binary Logistic Regression Model of the Associations 
Between Clinical Characteristics, Including a History of Hypertension (Present or 
Absent), and the Occurrence of Myocardial Hemorrhage (Yes or No) 2 Days Later 
(n=324) in Patients With Acute STEMI
Binary Logistic Regression
Odds Ratio (95% 
Confidence Interval) P Value
TIMI coronary flow grade 2/3 pre-PCI, 
n (%)
0.25 (0.12–0.51) <0.001
ST-segment elevation resolution post-PCI, n (%)
  Incomplete 30% to <70% 2.44 (1.31–4.53) 0.005
  None ≤30% 3.90 (1.69–9.02) 0.001
  Cigarette smoker 2.55 (1.39–4.70) 0.003
  Male sex 2.67 (1.33–5.38) 0.006
Hypertension 1.81 (0.98–3.34) 0.059
  Harrel’s C statistic: 0.746   
Manual backwards selection was used with a P value threshold of 0.10 
for inclusion. Previous PCI was excluded because of numeric instability. The 
C statistic reflects the whole model. The univariable association between 
hypertension and myocardial hemorrhage was 1.5 (0.87–2.59); 0.143. PCI 
indicates percutaneous coronary intervention; STEMI, ST-segment–elevation 
myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
Table 4. Multivariable Binary Logistic Regression Model for the Composite End 
Point (Yes or No) of All-Cause Death or First Hospitalization for Heart Failure, 
Including Clinical Characteristics (Present or Absent) at Baseline
Binary Logistic Regression
Odds Ratio (95% 
Confidence Interval) P Value
History of myocardial infarction 6.19 (2.40–15.95) <0.001
ST-segment elevation resolution post-PCI, n (%)
  Incomplete 30% to <70% 3.41 (1.54–7.56) 0.005
  None ≤30% 4.13 (1.55–11.06) 0.001
  Cigarette smoker 2.55 (1.39–4.70) 0.003
Hypertension 2.53 (1.28–4.98) 0.007
  Harrel’s C statistic: 0.746   
The median duration of follow-up was 4 y (1500 d [postdischarge censor 
duration (range) 1236–1801 d]). Forty-seven (15%) patients died or experienced 
a first heart failure event during the index hospitalization or postdischarge. 
Manual backwards selection was used with a P value threshold of 0.10 for 
inclusion. The C statistic reflects the whole model. The univariable association 
between hypertension and all-cause death or first hospitalization for heart 
failure was 2.52 (1.35–4.73); P=0.004. PCI indicates percutaneous coronary 
intervention.
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left ventricular mass in women with hypertension post-MI 
predisposes these individuals to adverse remodeling post-MI, 
and potentially, a worse cardiac prognosis in the longer term. 
Since the mean age of the participants was 59 years, an accel-
erated cardiovascular risk in postmenopausal women may 
be one contributing factor. Although reductions in mortality 
attributable to coronary heart disease have been observed in 
recent decades, no such decline has been observed in younger 
(<55 years) women.47 Further research seems warranted.
Antecedent Hypertension, Microvascular Function, 
and Myocardial Hemorrhage Post-MI
We studied the relationships between microvascular resistance 
measured directly in the culprit coronary artery at the time of 
the acute STEMI and antecedent hypertension. Surprisingly, 
hypertension was not associated with acute reperfusion injury, 
as revealed by direct intracoronary measurements of microvas-
cular resistance and by angiographic parameters (TIMI frame 
count, TIMI blush grade) or ST-segment resolution. The poten-
tial explanations for this finding include the prior use of anti-
hypertensive therapies, such as angiotensin-converting enzyme 
inhibitors, which have protective effects on vascular function,23 
and the similar levels of arterial BP at the time of hospital admis-
sion in patients with a history of hypertension compared with BP 
levels in patients with no history of hypertension. This finding is 
in-keeping with the beneficial effects of both lifestyle and phar-
macological measures to control BP. Because all of these param-
eters of coronary microvascular function are associated with 
prognosis post-MI,26,27,32 our findings rule out enhanced micro-
vascular injury within the infarct zone as an explanation for the 
adverse prognosis in patients with antecedent hypertension.
Myocardial hemorrhage occurs in about one-third of 
patients with acute STEMI.21,22 This pathology reflects the 
end-stage consequence of irreversible microvascular dysfunc-
tion and is independently associated with adverse cardiac out-
comes.21,22 In a time-course study,48 we have previously shown 
that myocardial hemorrhage occurs in 2 phases after coronary 
reperfusion. The first phase occurs acutely within 12 hours. 
The second phase involves new, secondary bleeds that occur 
between days 1 and 3 in previously unaffected patients.48 In 
this study, all patients who had evidence of new myocardial 
hemorrhage on day 3 had prior evidence of microvascular 
obstruction at 12 hours. We think that the temporal relation-
ships between microvascular obstruction and myocardial 
hemorrhage may be relevant when considering their associa-
tions with hypertension status.
Microvascular function measured acutely and micro-
vascular obstruction revealed by CMR 2 days later were 
not associated with hypertension status. However, myocar-
dial hemorrhage, as specifically revealed by T2* mapping 
(Figure 1) was associated with a near 2-fold increased risk of 
hypertension, independent of other predictors. The result was 
not statistically significant and thus hypothesis generating. 
Cigarette smoking status is a multivariable, positive associate 
of myocardial hemorrhage after an acute STEMI (Table 3)48 
and the inverse association between hypertension and smok-
ing status may be a relevant confounding factor.
We undertook a time-course study with repeated assess-
ments to assess the temporal evolution of microvascular injury 
acutely and then subsequently 2 to 3 days later using CMR. 
Long-term follow-up of this cohort permitted an analysis of the 
prognostic significance of microvascular injury early post-MI. 
Myocardial hemorrhage reflects vascular degradation and capil-
lary leak of red blood cells. Hemorrhage within the infarct zone 
as revealed by CMR (Figure 1) is a direct measure of end-stage 
vascular injury post-MI. Our findings lead to a conclusion that 
despite a similar extent of acute microvascular injury and infarct 
size, vascular degradation at 2 days is greater in patients with a 
history of hypertension compared with in patients with no prior 
hypertension. We hypothesize that the microvessels of patients 
with hypertension are less capable of maintaining vascular integ-
rity under conditions of ischemia/reperfusion injury.49 Given that 
hemorrhage may develop progressively in a secondary phase 
(days 2–3), impaired vascular homeostasis and repair poten-
tial in patients with chronic hypertension may be explanations 
for these results. Such patients may have preexisting coronary 
microvascular disease,15,16 and the microvessels subtended by the 
culprit artery may be less resistant to the effects of reperfusion 
injury (acidosis, oxidants, etc), leading to progressive capillary 
degradation and infarct zone hemorrhage. A susceptibility to 
hemorrhagic transformation within the infarct zone may provide 
a new mechanistic explanation for why patients with antecedent 
hypertension have a worse prognosis despite infarct size being 
similar to patients without prior hypertension.11,12 Accumulation 
of deoxyhemoglobin and iron within the infarct zone may serve 
as a mechanistic substrate for enhanced scar formation and 
abnormal left ventricular remodeling.50 Our results suggest that 
progressive microvascular damage within the infarct zone in 
patients with antecedent hypertension may underpin an impaired 
recovery potential within the heart, leading in turn to left ven-
tricular systolic dysfunction and heart failure in the longer term.
We did not find any association between hypertension sta-
tus and infarct size, as reflected by contrast-enhanced CMR 
and peak troponin concentration. This result is consistent 
with reports by Reinstadler et al11 and De Luca et al.12 We 
did not observe any association between hypertension status 
and circulating measures of inflammation. This result could 
potentially be explained by the anti-inflammatory effects of 
antihypertensive drug therapies, such as angiotensin-convert-
ing enzyme inhibitors.
Our results provide further evidence that a history of 
hypertension in patients with an acute STEMI is associated 
with a worse prognosis. In terms of clinical translation, our 
results highlight that patients with a history of hypertension 
are at an increased risk of developing heart failure. The results 
support further research into therapeutic strategies designed 
to preserve vascular integrity and repair potential within the 
vascular distribution of the culprit coronary artery.
Limitations
Our analysis does not permit inference on causality, and fur-
ther studies are warranted. We lacked detailed information on 
BP history and compliance with antihypertensive drug therapy 
before the index hospitalization.
Perspectives
In summary, we have studied the complex relationships 
between hypertension status, concomitant risk factors, 
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infarct pathology, left ventricular remodeling, and health 
outcomes in a large cohort of STEMI patients. We found 
that a history of hypertension in patients with acute STEMI 
is independently associated less improvement in left 
ventricular systolic function, notably in women, and an 
increased risk of all-cause death and heart failure in the 
longer term. An increased propensity to myocardial hem-
orrhage may be one mechanistic explanation, reflecting 
severe microvascular injury.
Our results confirm and extend previous investigations and 
support further research into therapeutic strategies that attenu-
ate reperfusion injury within the infarct zone in patients with 
acute STEMI.
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What Is New?
•	The pathological and prognostic significance of a history of hypertension 
was assessed in a reasonably large cohort of patients with acute ST-
segment–elevation myocardial infarction treated by emergency percuta-
neous coronary intervention.
•	Hypertension was associated with a near 2-fold increased likelihood of 
myocardial hemorrhage, reflecting severe microvascular injury.
•	Hypertension was associated with less favorable changes in left ven-
tricular ejection fraction and remodeling, notably in women, and hyper-
tension was associated with a higher risk of all-cause death and heart 
failure.
What Is Relevant?
•	A history of hypertension is associated with a worse prognosis.
•	Patients with acute ST-segment–elevation myocardial infarction and a 
history of hypertension merit intensive medical management.
Summary
Our results confirm and extend previous investigations and support 
further research into therapeutic strategies that attenuate reperfu-
sion injury within the infarct zone in patients with acute ST-seg-
ment–elevation myocardial infarction.
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